Acceptability of Formulations and Application Methods for Vaginal Microbicides Among Drug-involved Women: Results of Product Trials in Three Cities
Overview
Authors
Affiliations
Background And Objectives: Female-controlled methods of HIV prevention, such as vaginal microbicides, are urgently needed, particularly among drug-involved women. Acceptability research is critical to product development.
Goal: To assess the acceptability of forms and application methods for future microbicides.
Design: Eighty-four drug-involved women were introduced in groups to three lubricant products, asked to try each for 3 weeks, and scheduled for individual follow-up interviews.
Results: Participants and their partners felt positive about the products, and expressed willingness to use microbicides if they were shown to be effective against HIV. Women agreed on product characteristics that influenced their reactions (e.g. ease of insertion, degree of "messiness"), but often disagreed on whether their reactions to these characteristics were positive or negative.
Conclusion: Development of acceptable and effective HIV-prevention products depends on understanding the interaction between characteristics of the products and the characteristics and perceptions of women. Levels of sexual risk and acceptability factors based on drug-use patterns, race and ethnicity, culture, age, and types and attitudes of male partners suggest that a "one size fits all" approach will not win broad acceptance among drug-involved women.
Design aspects of vaginal applicators that influence acceptance among target users.
Bakke A, Zaveri T, Higgins M, Ziegler G, Hayes J Sci Rep. 2021; 11(1):9802.
PMID: 33963262 PMC: 8105386. DOI: 10.1038/s41598-021-89284-3.
Zaveri T, Powell K, Guthrie K, Bakke A, Ziegler G, Hayes J BMC Womens Health. 2018; 18(1):170.
PMID: 30342510 PMC: 6195955. DOI: 10.1186/s12905-018-0657-2.
Pines H, Semple S, Strathdee S, Hendrix C, Harvey-Vera A, Gorbach P BMC Public Health. 2018; 18(1):1009.
PMID: 30107833 PMC: 6092873. DOI: 10.1186/s12889-018-5946-z.
Zaveri T, Running C, Surapaneni L, Ziegler G, Hayes J Drug Deliv Transl Res. 2016; 6(5):551-64.
PMID: 27357703 PMC: 5011315. DOI: 10.1007/s13346-016-0309-8.
Zhang G, Zhang H, Yu H, Zhao Z, Yang J, Zhang M PLoS One. 2016; 11(5):e0156561.
PMID: 27243457 PMC: 4887105. DOI: 10.1371/journal.pone.0156561.